Fate Therapeutics (FATE) Operating Expenses (2012 - 2026)

Fate Therapeutics has reported Operating Expenses for 15 years, with the latest figure at $34.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 20.07% year-over-year to $34.3 million; the trailing twelve-month figure through Mar 2026 stood at $145.7 million (down 31.84% YoY), and the FY2025 full-year result was $154.4 million, down 31.07% from the prior year.
• Operating Expenses for Q1 2026 stood at $34.3 million, down from $36.1 million in the prior quarter.
• The five-year high for Operating Expenses was $108.8 million in Q4 2022, with the low at $34.3 million in Q1 2026.
• Historically, Operating Expenses has averaged $63.0 million across 5 years, with a median of $53.2 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 68.89% — and 2023, when it sank 54.26%.
• Fate Therapeutics' Operating Expenses stood at $108.8 million in 2022, then slumped by 54.26% to $49.8 million in 2023, then grew by 27.85% to $63.6 million in 2024, then slumped by 43.26% to $36.1 million in 2025, then dropped by 4.96% to $34.3 million in 2026.
• The last three Operating Expenses figures came in at $34.3 million (Q1 2026), $36.1 million (Q4 2025), and $36.5 million (Q3 2025), per Business Quant data.